Iovance Biotherapeutics, Inc. IOVA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s stock-based comp?
- Iovance Biotherapeutics, Inc. (IOVA) reported stock-based comp of $11.27M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s stock-based comp changed year-over-year?
- Iovance Biotherapeutics, Inc.'s stock-based comp decreased by 50.8% year-over-year, from $22.92M to $11.27M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s stock-based comp has grown at a -3.1% compound annual growth rate (CAGR), from $69.77M to $61.58M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.